Introduction {#sec1}
============

Carbon dioxide (CO~2~) is a very stable form of carbon, the central element of life on this planet and one of the simplest molecules that was probably highly abundant in the primeval earth atmosphere. This gas reacts with water, leading to H~2~CO~3~, which is an unstable compound that is spontaneously transformed into bicarbonate and protons. However, the reaction between CO~2~ and water is particularly slow at pH values of 7.5 or lower, which is usually the physiologic pH value in many tissues and organisms.^[@ref1]−[@ref3]^ Carbon dioxide hydration becomes, on the other hand, very effective at higher pH values, being instantaneous at pH \> 12.^[@ref1]−[@ref3]^ Moreover CO~2~ is an important molecule in all life processes, being generated in high amounts in most organisms.^[@ref3]−[@ref7]^ To catalyze its rapid transformation into bicarbonate, catalysts evolved in all life kingdoms, that is, the enzymes known as carbonic anhydrases (CAs, EC 4.2.1.1).^[@ref1]−[@ref7]^ Six genetically diverse such enzyme families are presently known---the α-, β-, γ-, δ-, ζ-, and η-CAs^[@ref6]−[@ref8]^---with the last class discovered quite recently.^[@ref9]^

CAs not only face the conversion of the high amounts of CO~2~ formed in the metabolic processes, transforming it in bicarbonate and protons, but they also manage the acid--base equilibria connected to this reaction. In fact, the products formed in the catalyzed reaction are either ions with strong buffering activity (bicarbonate) or hydrated protons (H^+^ ions). The regulation of pH is a highly important process in all life forms, since many biochemical reactions are tightly regulated by it.^[@ref1]−[@ref3]^ This is probably the reason why so many genetic CA families are presently known so that in some organisms, a multitude of different CA families with many isoforms have been described, each with specialized functions.^[@ref6]−[@ref9]^ The necessity of a tight/precise pH regulation may thus explain why most organisms investigated so far contain multiple CA isoforms, although they differ significantly by their catalytic activity, susceptibility to various classes of inhibitors, subcellular localization, and many other such features.^[@ref1]−[@ref3],[@ref6]−[@ref9]^ For example, in humans, 15 different CA isoforms, all belonging to the α-class, have been described.^[@ref1]−[@ref3]^

Most mammals (including humans) possess two blood isoforms, denominated CA I and CAII, with a total concentration of these proteins as high as 0.2 mM.^[@ref10]^ However, the catalytic activity of the human (h) isoform hCA I is much lower compared with that of hCA II, and in addition, hCA I is also inhibited by the chloride and bicarbonate present in the plasma, leaving a lot of questions regarding the physiologic function of this isoform.^[@ref10],[@ref11]^ On the other hand, the high activity isoform hCA II (also known as the "rapid" blood enzyme, to distinguish it from the "slow" one, hCA I) is involved in the secretion of electrolytes in a multitude of tissues, such as the bicarbonate-rich aqueous humor in the anterior chamber of the eyes, and the cerebrospinal fluid, but also in pH and CO~2~ homeostasis all over the body, as mentioned above.^[@ref11]−[@ref13]^ Other functions include urine formation and bicarbonate reabsorption in the kidney tubules; biosynthetic reactions, such as gluconeogenesis, lipogenesis, and ureagenesis; bone resorption and calcification; and probably many other less well understood physiological/pathological processes.^[@ref11]−[@ref15]^ Indeed, a dysregulation of the activity of these isoforms in one or more tissues has important pathologic consequences, such as glaucoma, when excessive aqueous humor is secreted within the eye, with the subsequent increase in the intraocular pressure (IOP) and edema, when not enough fluids are secreted/eliminated in the urine, leading to fluid accumulation in the body, processes in which CA II together with several other isoforms such as CA IV, XII, and XIV, are involved in the kidneys, epilepsy (the involvement of CA II and other brain CA isoforms in this disease is poorly understood and certainly not irrelevant), and some forms of cancer, in which CA II was observed to be overexpressed, alone or together with other isoforms such as CA IX and XII.^[@ref11]−[@ref15]^ CA II is also involved in other pathologies, such as acute mountain sickness and apparently, atherosclerosis and osteoporosis.^[@ref16]^

Primary sulfonamides constitute the main class of CA inhibitors (CAIs), with a number of such derivatives in clinical use for decades, mainly as antiglaucoma agents, diuretics, antiepileptics, or antiobesity drugs.^[@cit1c],[@cit1d],[@ref11]−[@ref16]^ Recently, some sulfonamides with CA inhibitory properties entered phase I clinical trials as antitumor/antimetastatic agents targeting hypoxic tumors in which two CA isoforms, CA IX and XII, are overexpressed.^[@cit1c],[@cit1d],[@ref17]^ The search for sulfonamide CAIs with various potentials in therapeutics is a dynamic research field, with many new classes being reported constantly and investigated in detail for inhibitory effects against mammalian and nonmammalian CAs.^[@ref1],[@ref17],[@ref18]^ Here, we report a class of 4-sulfamoylphenyl-ω-aminoalkyl ethers, a poorly investigated chemotype in the CAIs landscape, with interesting properties as antiglaucoma agents as well as for the design of fluorescent enzyme inhibitors with potential use for imaging CAs in various tissues.

Results and Discussion {#sec2}
======================

Chemistry and Drug Design {#sec2.1}
-------------------------

Benzenesulfonamides constitute a highly investigated class of CAIs,^[@cit19a]^ with most such compounds reported so far being derivatives of sulfanilamide, homosulfanilamide, or 4-aminoethylbenzenesulfonamide. Derivatization of the primary aliphatic/aromatic amino group from these compounds by its transformation into carboxamides, secondary sulfonamides, ureas, thioureas, or by reaction with pyrylium salts has led to a considerable number of new derivatives that showed excellent inhibitory properties against CA isoforms of medicinal interest, such as CA II, IV, VA/VB, IX, or XII.^[@ref16]−[@ref18],[@cit19a]^ This is generally known as the tail approach for designing CAIs.^[@cit18c]^ Surprisingly, very few benzenesulfonamides incorporating ether or thioether moieties have been reported so far. In fact, only one paper, by Vernier et al.,^[@cit19b]^ considered these chemotypes for the design of sulfonamide-based CAIs. In a very interesting study, these authors reported compounds of the type Ar-X-Ar′-SO~2~NH~2~, where X was O or S, and Ar, Ar′ aromatic/heterocyclic six-membered rings, which showed highly effective inhibitory properties against CA isoforms involved in important physiologic processes, such as CA II and IV.^[@cit19b]^ These derivatives showed improved water solubility compared with structurally similar sulfanilamide derivatives, possessed low nanomolar inhibitory action against CA II, and were shown to penetrate eye tissues, arriving at the ciliary processes where the enzyme is present within the eye, and participating in aqueous humor secretion.^[@cit19b]^ Unfortunately no in vivo antiglaucoma studies have been performed with those compounds that possessed physicochemical properties appropriate for an antiglaucoma drug candidate.

Considering these facts, we decided to explore the synthesis and properties of ethers incorporating the benzenesulfonamide "head" and aliphatic ether moieties of the type H~2~N--(CH~2~)~*n*~--O--C~6~H~4~--SO~2~NH~2~. As mentioned above, such ethers were not investigated as CAIs until now, and considering the aromatic derivatives reported by the Pfizer group,^[@cit19b]^ the presence of aliphatic, amino moieties should also promote the water solubility of the compounds. In fact, a considerable pharmacologic problem of the first generation CAIs, such as acetazolamide, AAZ; methazolamide, MZA; or dichlorophenamide, DCP, was their poor water solubility. Only the second generation drugs, such as dorzolamide, DRZ; and brinzolamide, BRZ, have an improved water solubility because these two topically acting antiglaucoma drugs are administered as hydrochloride salts (both weak amines).

![](jm-2014-01497m_0028){#fig100}

![Preparation of the Sulfonamides **4, 5, 7**, and **9** Reported in This Paper](jm-2014-01497m_0006){#sch1}

Thus, we designed the following strategy for obtaining the 4-sulfamoylphenyl ω-aminoalkyl ethers reported in this paper (Scheme [1](#sch1){ref-type="scheme"}). Reaction of ω-amino-alcohols **1a**--**e** (*n* = 2--6) with *tert*-butyloxycarbonyl anhydride afforded the Boc-protected amines **2a**--**e**,^[@ref20]^ which by Mitsunobu reaction with 4-hydroxybenzenesulfonamide **3** led to the Boc-protected derivatives **4a**--**e**.^[@ref21]^ Removal of the protecting group in the presence of trifluoroacetic acid (TFA) afforded the trifluoroacetate salts of the 4-sulfamoylphenyl ω-aminoalkyl ethers **5a**--**e** (Scheme [1](#sch1){ref-type="scheme"}). The alkyl chain present in the new derivatives ranged between 2 and 6 carbon atoms to investigate the influence of the spacer length for the enzyme inhibitory properties of the new derivatives.

Another aspect in the design of CAIs is related to the use of such compounds as diagnostic tools, for example, for the imaging of tumors in which some CA isoforms are overexpressed. We have reported, for example, fluorescein-based sulfonamides (obtained again from sulfanilamide, homosulfanilamide or 4-aminoethylbenzenesulfonamide, which were reacted with fluorescein isothiocyanate)^[@ref22]^ that were essential for demonstrating the role of CA IX/XII in the acidification of the extracellular tumor milieu and also in the proof-of-concept studies regarding the druggability of these novel antitumor targets.^[@ref23]^ However, like most aromatic thioureas, the fluorescent sulfonamides reported earlier showed a rather low water solubility, which may be a limiting factor for some of their applications. Thus, we report here novel derivatives that were prepared by reaction of the 4-sulfamoylphenyl ω-aminoalkyl ethers **5a**--**e** with fluorescein isothiocyanate **6** or \[9-(2-carboxy-4-isothiocyanato-phenyl)-6-dimethylaminoxanthen-3-ylidene\]-dimethylammonium chloride **8**, leading to the novel fluorescent compounds of types **7a**--**c** and **9a**,**b**, respectively (Scheme [1](#sch1){ref-type="scheme"}). The last compounds (**9a**,**b**) incorporate a fluorophore that was not investigated earlier for its interaction with CAs.

###### hCA I, II, IX, and XII Inhibition Data of the Newly Synthesized Sulfonamides **4a**--**9b** and Acetazolamide AAZ as Standard, by the Stopped Flow CO~2~ Hydrase Assay^[@ref24]^

           *K*~i~ (nM)[a](#t1fn1){ref-type="table-fn"}                 
  -------- --------------------------------------------- ------ ------ ------
  **4a**   5.3                                           5.0    8.3    7.2
  **4b**   6.6                                           5.1    5.8    6.5
  **4c**   41.2                                          5.7    7.7    6.6
  **4d**   7.9                                           5.5    7.1    5.7
  **4e**   6.1                                           5.2    6.9    6.4
  **5a**   649                                           66.5   8.7    88.5
  **5b**   452                                           36.6   17.9   9.6
  **5c**   286                                           8.9    32.6   7.5
  **5d**   52.5                                          8.8    6.6    7.3
  **5e**   63.0                                          3.9    6.5    6.5
  **7a**   18.0                                          5.0    8.5    8.6
  **7b**   17.1                                          4.6    7.2    5.7
  **7c**   90.9                                          3.9    8.8    7.1
  **9a**   826                                           215    9.6    609
  **9b**   151                                           43.3   7.9    36.7
  AAZ      250                                           12.1   25.0   5.7

Mean from three different assays; errors are in the range of ±10% of the reported value.

Carbonic Anhydrase Inhibition {#sec2.2}
-----------------------------

Inhibition data against four physiologically significant CA isoforms, that is, h (human) hCA I, II, IX, and XII, are shown in Table [1](#tbl1){ref-type="other"}. The following structure--activity relationship (SAR) can be drawn from the data of Table [1](#tbl1){ref-type="other"}:

\(i\) The slow human isoform hCA I effectively inhibited by some of the sulfonamides investigated here, such as **4a**--**4e** and **7a**, **7b**, which showed *K*~I~ values in the low nanomolar range (5.3--41.2 nM), whereas other derivatives (e.g., **5d**, **5e**, and **7c**) were medium potency inhibitors, with *K*~I~'s of 52.5--90.9 nM. Like acetazolamide AAZ, some of the new compounds, among which **5a**--**5c** and **9a**, **9b** were less effective hCA I inhibitors, with *K*~I~'s of 151--826 nM. Thus, the best hCA I inhibitors were the Boc-protected derivatives **4**, which showed a rather compact behavior of very effective inhibitor, except for the compound with the 4-carbon-atoms linker (**4c**) which was less effective compared with its congeners **4a**, **b**, **d**, and **e**. The deprotected amines **5** were less effective as hCA I inhibitors compared with the corresponding Boc derivatives (Table [1](#tbl1){ref-type="other"}). Among the fluorescent CAIs reported here, the fluorescein-containing compounds **7a** and **7b** were effective hCA I inhibitors, whereas the tetramethylrhodamine derivatives **9a** and **9b** were much less effective as hCA I inhibitors compared with the fluorescein derivatives mentioned above.

\(ii\) The physiologically dominant hCA II very effectively inhibited by most sulfonamides reported here. Indeed, just four compounds (**5a** and **5b**) as well as **9a**,**b** showed medium potency activity, with *K*~I~'s of 36.6--215 nM. The remaining sulfonamides showed very effective hCA II inhibitory properties, with *K*~I~'s ranging between 3.9 and 8.9 nM (Table [1](#tbl1){ref-type="other"}) and are thus more effective than the clinically used drug acetazolamide AAZ. The SAR is rather clear-cut: the five BOC-protected derivatives **4a**--**4e** showed a very compact behavior with basically no variation of the inhibitory power, with the length of the linker from 2 to 6 CH~2~ moieties. However, the situation is changed for the amines **5a**--**5e**, which on one hand were weaker hCA II inhibitors compared with the corresponding Boc-protected derivatives and on the other hand showed an increase in the inhibitory power with an increase in the linker chain from 2 to 6 CH~2~ moieties. Indeed, between compounds **5a** and **5e**, there is a 17-fold difference in the inhibitory activity against this isoform. As for hCA I inhibition, again, the fluorescein-tailed sulfonamides **7a**--**7c** were much more inhibitory compared with the tetramethylrhodamine derivatives **9a** and **9b.**

\(iii\) The tumor-associated, transmembrane isoform hCA IX was very well inhibited by all derivatives reported here, with *K*~I~'s of 5.8--32.6 nM. The SAR is almost impossible to delineate because all these compounds show excellent inhibitory activity. For example, the Boc-protected derivatives **4a**--**e** have a minimal variation of the inhibition constants, ranging between 5.8 and 8.3 nM. This variation is slightly higher for the amines **5** (between 6.5 and 32.6 nM) and is again almost absent for the fluorescent sulfonamides **7** and **9**. It is interesting to note that for this isoform, both the fluorescein and the tetramethylrhodamine derivatives were equally effective as CAIs.

\(iv\) The other transmembrane isoform investigated here, hCA XII, was also effectively inhibited by most of the new sulfonamides reported in this paper. Two compounds, **5a** and **9b**, were medium potency inhibitors (*K*~I~'s of 36.7--88.5 nM), and one (**9a**) was an ineffective inhibitor (*K*~I~ of 609 nM). The remaining sulfonamides investigated here showed excellent hCA XII inhibitory activity, with inhibition constants ranging between 5.4 and 9.6 nM, again with no obvious SAR to be discussed (Table [1](#tbl1){ref-type="other"}).

\(v\) Although most of these sulfonamides were effective CAIs against all four isoforms investigated here, several interesting selectivity cases were observed: for example, **9a** is a hCA IX-selective sulfonamide inhibitor, with a *K*~I~ of 9.6 nM against the tumor-associated isoform and \>215 nM against hCA I, II, and XII (Table [1](#tbl1){ref-type="other"}). Compound **5b** effectively inhibits the two transmembrane isoforms (*K*~I~'s of 9.6--17.9 nM); it is a much less effective inhibitor of the two cytosolic isoforms hCA I and II (*K*~I~'s of 36.6--452 nM).

###### Crystallographic Statistics for the hCA II Adducts of **4c** and **5c**[a](#t2fn3){ref-type="table-fn"}

                                                                           hCA II-**4c**                                   hCA II-**5c**
  ------------------------------------------------------------------------ ----------------------------------------------- -----------------------------------------------
  PDB ID                                                                   4RFC                                            4RFD
  space group                                                              P2~1~                                           P2~1~
  unit-cell parameters (Å, deg)                                            *a* = 42.4, *b* = 41.3, *c* = 71.7, β = 104.1   *a* = 42.5, *b* = 41.3, *c* = 72.1, β = 104.3
  resolution (Å)                                                           1.80 (1.86--1.80)                               1.63 (1.69--1.63)
  total no. reflections                                                    71 626                                          105 407
  individual reflections                                                   22 386                                          30 415
  redundancy                                                               3.2                                             3.5
  completeness                                                             98.8 (99.5)                                     99.7 (97.9)
  *R*~sym~[b](#t2fn1){ref-type="table-fn"}                                 0.163                                           0.086
  *R*~cryst~/*R*~free~[c](#t2fn2){ref-type="table-fn"}                     0.224/0.260                                     0.178/0.206
  rmsd for bond lengths/angles (Å, deg)                                    0.006/1.10                                      0.010/1.29
  av B-factors (Å^2^) main/side/ligand                                     12.3/16.7/                                      5.3/9.1/
  no. protein atoms                                                        2086                                            2114
  no. water molecules                                                      54                                              127
  Ramachandran statistics most favored and additional/generously allowed   89.4/10.5/0.5                                   87.6/11.5/0.9

Values in parentheses represent highest resolution bin.

*R*~sym~ = (∑\|I - ⟨I⟩\|/∑ ⟨I⟩).

*R*~cryst~ = (∑\|*F*~0~ -- *F*~c~\|/∑ \|*F*~0~\|). *R*~free~ is calculated in the same way as *R*~cryst~ except it is for data omitted from refinement (5% of reflections for all data sets).

![Electron density of compound **4c** bound within the hCA II active site. The Zn(II) ion (gray sphere) and its three His ligands (His94, 96, and 119) as well as other residues involved in the catalytic cycle or binding with inhibitors are shown. The 2*F*~0~ -- *F*~c~ electron density is represented by a 0.6σ-weighted gray mesh. Because of the less-ordered electron density for the tail region of **4c**, its map was contoured at a lower sigma level compared with compound **5c**.](jm-2014-01497m_0002){#fig1}

![Electron density of compound **5c** bound within the hCA II active site. The Zn(II) ion (gray sphere) and its three His ligands (His94, 96, and 119) as well as other residues involved in the catalytic cycle or binding with inhibitors are shown. The 2*F*~0~ -- *F*~c~ electron density is represented by a 1.0σ-weighted gray mesh.](jm-2014-01497m_0003){#fig2}

![Overlay of sulfonamides **4c** (orange) and **5c** (teal) bound within the active site of hCA II. Hydrophobic region, red; hydrophilic region, blue; zinc ion, gray sphere at the bottom of the activity.](jm-2014-01497m_0004){#fig3}

X-ray Crystallography {#sec2.3}
---------------------

To rationalize some of the inhibition data presented above, two of the novel sulfonamides reported here, **4c** (incorporating the Boc-aminobutyl moiety) and **5c** (incorporating the 4-aminobutyl fragment) were cocrystallized with hCA II, and their crystal structures were resolved at a high resolution (Table [2](#tbl2){ref-type="other"}). Both inhibitors were observed bound within the enzyme active site, coordinating to the Zn(II) ion by means of the deprotonated nitrogen of the sulfonamide moiety (Figures [1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}), like all other sulfonamide or sulfamates investigated so far by means of this technique.^[@ref1],[@ref25],[@ref26]^ The phenyl ring and the rather long, hydrophobic alkyl tails of both inhibitors were observed to interact only with residues of the hydrophobic half of the hCA II active site (as shown in Figures [1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}), such as Val121, Phe131, Leu198, Pro201, and Pro202. The tail of compound **5c** extends farther out into the enzyme's hydrophobic cleft, allowing it to form more stabilizing interactions with amino acids, such as Pro201 and Leu204; however, the shorter tail of compound **4c** is unable to perform such interactions (Figure [3](#fig3){ref-type="fig"}).

It should be mentioned that for the Boc-protected derivative **4c**, the electron density of the tail region was not completely defined (Figure [1](#fig1){ref-type="fig"}), probably because of its high flexibility and disorder when complexed to the enzyme. In contrast, for the amine **5c**, all atoms from the tail region had the electron density well-defined, proving that this region is less disordered compared with the Boc-protected compound **4c** (Figure [2](#fig2){ref-type="fig"}). To account for this disorder and to ensure the ligand was built into the density correctly, the map for compound **4c** was contoured at a lower sigma level (0.6) than that of **5c** (1.0). The fact that the tails of these compounds lie only in the hydrophobic cleft of the hCA II active site is a noteworthy finding, because we showed in earlier papers^[@ref25],[@ref26]^ that the active site region (hydrophobic versus hydrophilic halves) in which a sulfonamide binds is indicative of its isoform-selectivity properties. In fact, we observed earlier that compounds that have their tails lying only in the hydrophobic half generally do not possess isoform-selective inhibitory properties, and this is also confirmed by the present findings (although neither **4c** nor **5c** is highly effective as hCA I inhibitors, Table [1](#tbl1){ref-type="other"}). In fact, these two compounds inhibit hCA II, IX, and XII in rather similar ranges and are effective inhibitors against these three isoforms. Because our interest was to obtain compound with antiglaucoma activity, for which both hCA II and XII^[@ref27]^ effective inhibitory properties are desired, we consider the present observations of real interest.

![Drop of intraocular pressure (ΔIOP, mmHg) versus time (min) in hypertonic saline-induced ocular hypertension in rabbits, treated with 50 μL of 2% solution of compounds **4c**, **5c**, and DRZ as the standard drug and vehicle. Errors were within 10--15% of the reported IOP values (from three different measurements for each of the four animals in the study group) and were statistically significant (*p* = 0.045 by the Student's *t* test).](jm-2014-01497m_0005){#fig4}

Antiglaucoma Activity {#sec2.4}
---------------------

Both the Boc-protected and the amino derivative sulfonamides reported here showed excellent water solubility and could be formulated as 2% eye drops at the neutral pH value (dorzolamide, DRZ, the clinically used drug is a hydrochloride salt with a pH of the eye drops of 5.5 which produces eye irritation and stinging as side effects).^[@ref11]^ We have investigated the intraocular pressure (IOP) lowering properties of some of these compounds, more precisely, **4c** and **5c** (for which the X-ray in adduct with hCA II was reported; see the [Discussion](#sec2){ref-type="other"} section, above), in an animal model of glaucoma.^[@ref28]^ Indeed, both compounds were low nanomolar inhibitors of isoforms hCA II (responsible for aqueous humor secretion) and hCA XII (isoform that is overexpressed in the eyes of glaucomatous patients).^[@ref27]^ As seen from the data of Figure [4](#fig4){ref-type="fig"}, the Boc-protected derivative **4c** showed a small decrease of IOP (of 1--2.5 mmHg) when given topically to the eye of the animals, whereas the free amine **5c** (as a trifluoroacetate salt) was more effective, with an IOP decrease of 4.4 mmHg at 2 h postadministration, more effective than DRZ, the standard drug, which caused an IOP drop of 4 mmHg at 60 min postadministration. Another notable difference between **5c** and DRZ was the fact that the new compound investigated here had a prolonged efficacy compared to DRZ, for which after 4 h no IOP decrease was seen. In contrast, **5c** showed efficacy even after 4 h postadministration, with an IOP drop of 3 mmHg at that time point. It should be mentioned that the animal model employed here is of normotensive rabbits,^[@ref28]^ and this is why the absolute IOP drops are not very high, but the advantage of this model is that the measurements can be done rapidly and are highly reproducible.^[@cit14a]^

Conclusions {#sec3}
===========

We report a series of new 4-sulfamoylphenyl-ω-aminoalkyl ethers that have been prepared by Mitsunobu reaction. Interesting SAR has been observed for the inhibition of four physiologically relevant CA isoforms: hCA I, II, IX, and XII. Many of the new compounds were highly effective inhibitors of all these isoforms, in the low nanomolar range, with few isoform-selective compounds also identified. These findings have been rationalized by resolving the X-ray crystal structures of two of the new sulfonamides. The tails of these derivatives were observed bound only in the hydrophobic half of the enzyme active site, making van der Waals contacts with amino acids such as Val135, Leu198, Leu204, Trp209, Pro201. and Pro202. One of the compounds incorporating a free amine moiety, which was highly water-soluble as a trifluoroacetate salt, also showed effective IOP lowering properties in an animal model of glaucoma. Several fluorescent sulfonamides have also been reported that incorporate either fluorescein--thiourea or tetramethylrhodamine--thiourea moieties, which also effectively inhibited some CA isoforms investigated here.

Experimental Protocols {#sec4}
======================

Chemistry {#sec4.1}
---------

Anhydrous solvents and all reagents were purchased from Sigma-Aldrich, Alfa Aesar, and TCI. All reactions involving air- or moisture-sensitive compounds were performed under a nitrogen atmosphere using dried glassware and syringe techniques to transfer solutions. Nuclear magnetic resonance (^1^H NMR, ^13^C NMR, DEPT-135, DEPT-90, HSQC, HMBC) spectra were recorded using a Bruker Advance III 400 MHz spectrometer in DMSO-*d*~6~. Chemical shifts are reported in parts per million (ppm), and the coupling constants (*J*) are expressed in Hertz (Hz). Splitting patterns are designated as follows: s, singlet; d, doublet; sept, septet; t, triplet; q, quadruplet; m, multiplet; brs, broad singlet; dd, double of doubles, appt, apparent triplet, appq, apparent quartet. The assignment of exchangeable protons (O*H* and N*H*) was confirmed by the addition of D~2~O. Analytical thin-layer chromatography (TLC) was carried out on Merck silica gel F-254 plates. Flash chromatography purifications were performed on Merck Silica gel 60 (230--400 mesh ASTM) as the stationary phase and ethyl acetate/*n*-hexane were used as eluents. Melting points (mp) were measured in open capillary tubes with a Gallenkamp MPD350.BM3.5 apparatus and are uncorrected. All compounds reported here were \>95% HPLC pure.

General Procedure for the Synthesis of *O*-Alkylbenzenesulfonamides **5a--e** via Mitsunobu coupling {#sec4.2}
----------------------------------------------------------------------------------------------------

### a. General Procedure for Boc Protection {#sec4.2.1}

Aminoalcohol **1a**--**e** (1.0 equiv) was dissolved in dichloromethane (DCM) and treated with a 1 M NaOH aqueous solution or diisopropyl ethylamine (DIPEA) (1.0 equiv), then di-*tert*-butyl dicarbonate (1.0 equiv) was added, and the mixture was vigorously stirred O.N. until consumption of starting materials (TLC monitoring). The reaction was quenched with a 1 M hydrochloric acid aqueous solution, neutralized with NaHCO~3~ aqueous solution, and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo to give the titled product.

### b. General Procedure for Mitsunobu Coupling {#sec4.2.2}

Boc-aminoalchol **2a**--**e** (1.0 equiv) was dissolved in dry THF and transferred to a two neck-flask via cannula, followed by addition of Ph~3~P (1.0 equiv) and 4-hydroxybenzenesulfonamide (1.0 equiv). Then the solution was cooled to 0 °C, and diisopropyl azodicarboxylate (DIAD) (1.1 equiv) was added dropwise. The reaction was warmed to r.t. and stirred at the same temperature until the starting materials were consumed (TLC monitoring), quenched with slush, and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo to give a residue that was purified by silica gel column chromatography followed by crystallization when necessary.

### c. General Procedure for Boc Deprotection {#sec4.2.3}

Compounds **4a**--**e** (1.0 equiv) was dissolved in DCM or 1,4-dioxane and treated with TFA. The reaction was stirred at r.t. until the starting material was consumed (TLC monitoring). The solvent was removed under vacuo, and the obtained residue was crystallized from IPA or triturated from diethyl ether to obtain the titled compound as a white solid.

#### Synthesis of *tert*-Butyl 2-Hydroxyethylcarbamate **2a** {#sec4.2.3.1}

![](jm-2014-01497m_0008){#fx1}

Ethanolamine **1a** (1.0 g, 1.0 equiv) was dissolved in DCM (16.5 mL) and treated with a 1 M aqueous solution of NaOH (1.0 equiv), and then di-*tert*-butyl dicarbonate (1.0 equiv) was added. The reaction mixture was treated according to the general procedure [a](#sec4.2.1){ref-type="other"}, previously reported, to give the titled compound **2a** as a colorless liquid, which was used as it is.

##### *tert*-Butyl 2-Hydroxyethylcarbamate **2a**: {#sec4.2.3.1.1}

66% yield; silica gel TLC *R*~*f*~ 0.18 (ethyl acetate/*n*-hexane 50% v/v); δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (9H, s), 3.0 (2H, q, *J* 6.0), 3.38 (2H, t, *J*, 6.0), 4.6 (1H, t, *J* 6.0, exchange with D~2~O, O*H*), 6.71 (1H, brt, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 29.2, 43.6, 61.0, 78.4, 156.6. Experimental data are in agreement with reported data.^[@ref29]^

#### Synthesis of *tert*-Butyl 3-Hydroxypropylcarbamate **2b** {#sec4.2.3.2}

![](jm-2014-01497m_0009){#fx2}

3-Amino-1-propanol **1b** (0.98 g, 1.0 equiv) was dissolved in DCM (13 mL) and treated with a 1 M aqueous solution of NaOH (1.0 equiv), and then di-*tert*-butyl dicarbonate (1.0 equiv) was added. The reaction mixture was treated according to the general procedure [a](#sec4.2.1){ref-type="other"}, previously reported, to give the titled compound **2b** as a colorless liquid, which was used as it is.

##### *tert*-Butyl 3-Hydroxypropylcarbamate **2b**: {#sec4.2.3.2.1}

80% yield; silica gel TLC *R*~*f*~ 0.18 (ethyl acetate/*n*-hexane 50% v/v); δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (9H, s), 1.55 (2H, pent, *J* 6.4), 3.0 (2H, q, *J* 6.4), 3.42 (2H, q, *J*, 6.0), 4.4 (1H, t, *J* 6.0, exchange with D~2~O, O*H*), 6.76 (1H, brt, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 29.2, 33.7, 38.1, 60.7, 78.3, 156.5. Experimental data are in agreement with reported data.^[@ref30]^

#### Synthesis of *tert*-Butyl 4-Hydroxybutylcarbamate **2c** {#sec4.2.3.3}

![](jm-2014-01497m_0010){#fx3}

4-Amino-1-butanol **1c** (1.45 g, 1.0 equiv) was dissolved in DCM (16 mL) and treated with DIPEA (1.0 equiv) and then di-*tert*-butyl dicarbonate (1.0 equiv). The reaction mixture was treated according to the general procedure [a](#sec4.2.1){ref-type="other"}, previously reported, to give the titled compound **2c** as a yellow liquid, which was used as it is.

##### *tert*-Butyl 4-Hydroxybutylcarbamate **2c**: {#sec4.2.3.3.1}

70% yield; silica gel TLC *R*~*f*~ 0.16 (ethyl acetate/*n*-hexane 50% v/v); δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (13H, s), 2.93 (2H, m), 3.40 (2H, m), 4.39 (1H, t, *J*, 5.0, exchange with D~2~O, O*H*), 6.80 (1H, t, *J* 6.0, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 27.2, 29.2, 30.8, 40.7, 61.4, 78.2, 156.5. Experimental data are in agreement with reported data.^[@ref31]^

#### Synthesis of *tert*-Butyl 5-Hydroxypentylcarbamate **2d** {#sec4.2.3.4}

![](jm-2014-01497m_0011){#fx4}

5-Amino-1-pentanol **1d** (1.5 g, 1.0 equiv) was dissolved in DCM (14.5 mL) and treated with a 1 M aqueous solution of NaOH (1.0 equiv) and then di-*tert*-butyl dicarbonate (1.0 equiv). The reaction mixture was treated according to the general procedure [a](#sec4.2.1){ref-type="other"}, previously reported, to give the titled compound **2d** as a yellow liquid, which was used as it is.

##### *tert*-Butyl 5-Hydroxypentylcarbamate **2d**: {#sec4.2.3.4.1}

77% yield; silica gel TLC *R*~*f*~ 0.3 (ethyl acetate/*n*-hexane 60% v/v); δ~H~ (400 MHz, DMSO-*d*~6~) 1.22--1.32 (2H, m), 1.34--1.48 (13H, m) 2.92 (2H, q, *J* 6.4), 3.39 (2H, m), 4.36 (1H, t, *J* 5.2, exchange with D2O, O*H*), 6.79 (1H, brt, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 23.8, 29.2, 30.3, 33.1, 40.8, 61.6, 78.2, 156.5. Experimental data are in agreement with reported data.^[@cit30b]^

#### *tert*-Butyl 6-Hydroxyhexylcarbamate **2e** {#sec4.2.3.5}

![](jm-2014-01497m_0012){#fx5}

6-Amino-1-hexanol **1e** (0.1 g, 1 equiv) was dissolved in DCM (8.5 mL) and treated with a DIPEA (1.0 equiv) and di-*tert*-butyl dicarbonate (1.0 equiv). The reaction mixture was treated according to the general procedure [a](#sec4.2.1){ref-type="other"}, previously reported, to give the titled compound **2e** as a colorless oil, which was used as it is.

##### *tert*-Butyl 6-Hydroxyhexylcarbamate **2e**: {#sec4.2.3.5.1}

81% yield; silica gel TLC *R*~*f*~ 0.2 (ethyl acetate/*n*-hexane 50% v/v); δ~H~ (400 MHz, DMSO-*d*~6~) 1.23--1.34 (4H, m), 1.34--1.48 (13H, m), 2.89 (2H, q, *J* 6.7), 3.36 (2H, q, *J* 5.2), 4.3 (1H, t, *J* 5.2, exchange with D~2~O, O*H*), 6.76 (1H, brt, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 26.2, 27.1, 29.2, 30.5, 33.4, 40.7, 61.6, 78.2, 156.5. Experimental data are in agreement with reported data.^[@ref32]^

#### Synthesis of *tert*-Butyl 2-(4-Sulfamoylphenoxy)-ethylcarbamate **4a** {#sec4.2.3.6}

![](jm-2014-01497m_0013){#fx6}

*tert*-Butyl 2-hydroxyethylcarbamate **2a** (1.0 g, 1.0 equiv) was dissolved in dry THF (9.5 mL) and was treated with Ph~3~P (1.0 equiv), 4-hydroxybenzenesulfonamide **3** (1.0 equiv), and DIAD (1.1 equiv) according to the general procedure [b](#sec4.2.2){ref-type="other"}, previously reported. The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). The reaction was quenched with slush and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo, and the obtained residue was purified by silica gel column chromatography eluting with ethyl acetate/*n*-hexane 60% v/v, followed by crystallization in EtOH/H~2~O mixture to afford the titled compound **4a** as a white solid.

##### *tert*-Butyl 2-(4-Sulfamoylphenoxy)-ethylcarbamate **4a**: {#sec4.2.3.6.1}

40% yield, silica gel TLC *R*~*f*~ 0.4 (ethyl acetate/*n*-hexane 60% v/v); mp 148--149 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.42 (9H, s), 3.33 (2H, t, *J* 5.6), 4.07 (2H, t, *J*, 5.6), 7.07 (1H, brt, exchange with D2O, N*H*), 7.1 (2H, d, *J* 8.8), 7.24 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.77 (2H, d, *J* 8.8); δ~C~ (100 MHz, DMSO-*d*~6~) 29.4, 40.3, 68.0, 79.2, 115.7, 128.9, 137.2, 156.9, 162.0. Elemental analysis: calcd C 49.35, H 6.37, N 8.85, S 10.14; found C 49.43, H 6.03, N 8.68, S 9.97; *m*/*z* (ESI negative) 315.6 \[M -- H\]^−^.

#### Synthesis of *tert*-Butyl 3-(4-Sulfamoylphenoxy)-propylcarbamate **4b** {#sec4.2.3.7}

![](jm-2014-01497m_0014){#fx7}

*tert*-Butyl 3-hydroxypropylcarbamate **2b** (0.88 g, 1.0 equiv) was dissolved in dry THF (4.7 mL) and was treated with Ph~3~P (1.0 equiv), 4-hydroxybenzenesulfonamide **3** (1.0 equiv), and DIAD (1.1 equiv) according to the general procedure [b](#sec4.2.2){ref-type="other"}, previously reported. The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). The reaction was quenched with slush and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo, and the obtained residue was purified by silica gel column chromatography eluting with ethyl acetate/*n*-hexane 55% v/v, followed by crystallization in IPA to afford the titled compound **4b** as a white solid.

##### *tert*-Butyl 3-(4-sulfamoylphenoxy)-propylcarbamate **4b**: {#sec4.2.3.7.1}

21% yield, silica gel TLC *R*~*f*~ 0.35 (ethyl acetate/*n*-hexane 55% v/v); mp 134--135 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (9H, s), 1.88 (2H, pent, *J* 6.4), 3.10 (2h, q, *J* 6.4), 4.08 (2H, t, *J*, 6.4), 6.95 (1H, t, *J* 6.4, exchange with D2O, N*H*), 7.09 (2H, d, *J* 8.8), 7.23 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.77 (2H, d, *J* 8.8); δ~C~ (100 MHz, DMSO-*d*~6~) 29.2, 30.0, 37.7, 66.6, 78.5, 115.3, 128.6, 137.0, 156.6, 161.9. Elemental analysis: calcd C 50.89, H 6.71, N 8.48, S 9.70; found C 51.09, H 7.01, N 8.64, S 9.54; *m*/*z* (ESI negative) 329.40 \[M -- H\]^−^.

#### Synthesis of *tert*-Butyl 4-(4-Sulfamoylphenoxy)-butylcarbamate **4c** {#sec4.2.3.8}

![](jm-2014-01497m_0015){#fx8}

*tert*-Butyl 4-hydroxybutylcarbamate **2c** (1.11 g, 1.0 equiv) was dissolved in dry THF (10.0 mL) and was treated with Ph~3~P (1.0 equiv), 4-hydroxybenzenesulfonamide **3** (1.0 equiv), and DIAD (1.1 equiv) according to the general procedure [b](#sec4.2.2){ref-type="other"}, previously reported. The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). The reaction was quenched with slush and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo, and the obtained residue was purified by silica gel column chromatography eluting with 60% v/v ethyl acetate/*n*-hexane to afford the titled compound **4c** as a white solid.

##### *tert*-Butyl 4-(4-Sulfamoylphenoxy)-butylcarbamate **4c**: {#sec4.2.3.8.1}

22% yield, silica gel TLC *R*~*f*~ 0.40 (ethyl acetate/*n*-hexane 60% v/v); mp 93--94 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (9H, s), 1.56 (2H, m), 1.74 (2H, m), 3.10 (2h, q, *J* 6.5), 4.08 (2H, t, *J* 6.5), 6.95 (1H, t, *J* 5.2, exchange with D~2~O, N*H*), 7.09 (2H, d, *J* 8.8), 7.23 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.77 (2H, d, *J* 8.8); δ~C~ (100 MHz, DMSO-*d*~6~) 26.9, 27.0, 29.2, 30.2, 68.6, 78.4, 115.4, 128.6, 137.0, 156.6, 162.0; Elemental analysis: calcd C 52.31, H 7.02, N 8.13, S 9.31; found C 52.65, H 6.76, N 8.01, S 8.91; *m*/*z* (ESI negative) 343.17 \[M -- H\]^−^.

#### Synthesis of *tert*-Butyl 5-(4-Sulfamoylphenoxy)-pentylcarbamate **4d** {#sec4.2.3.9}

![](jm-2014-01497m_0016){#fx9}

*tert*-Butyl 5-hydroxypentylcarbamate **2d** (1.2 g, 1.0 equiv) was dissolved in dry THF (9.0 mL) and was treated with Ph~3~P (1.0 equiv), 4-hydroxybenzenesulfonamide **3** (1.0 equiv), and DIAD (1.1 equiv) according to the general procedure [b](#sec4.2.2){ref-type="other"}, previously reported. The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). The reaction was quenched with slush and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo, and the obtained residue was purified by silica gel column chromatography, eluting with 60% v/v ethyl acetate/*n*-hexane to afford the titled compound **4d** as a white solid.

##### *tert*-Butyl 5-(4-Sulfamoylphenoxy)-pentylcarbamate **4d**: {#sec4.2.3.9.1}

27% yield, silica gel TLC *R*~*f*~ 0.42(ethyl acetate/*n*-hexane 60% v/v); mp 95--96 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.37--1.51 (13H, m), 1.73 (2H, pent, *J* 6.8), 2.94 (2H, q, *J* 6.4), 4.04 (2H, t, *J* 6.4), 6.80 (1H, t, *J* 5.7, exchange with D~2~O, N*H*), 7.08 (2H, d, *J* 8.8), 7.20 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.75 (2H, d, *J* 8.8); δ~C~ (100 MHz, DMSO-*d*~6~) 23.6, 29.1, 29.2, 30.1, 40.6, 68.7, 78.2, 115.3, 128.6, 136.9, 156.5, 162.0; Elemental analysis: calcd C 53.61, H 7.31, N 7.82, S 8.95; found C 53.50, H 7.01, N 7.87, S 8.69; *m*/*z* (ESI negative) 357.60 \[M -- H\]^−^.

#### Synthesis of *tert*-Butyl 6-(4-Sulfamoylphenoxy)-hexylcarbamate **4e** {#sec4.2.3.10}

![](jm-2014-01497m_0017){#fx10}

*tert*-Butyl 6-hydroxyhexylcarbamate **2e** (1.37 g, 1.0 equiv) was dissolved in dry THF (9.0 mL) and was treated with Ph~3~P (1.0 equiv), 4-hydroxybenzenesulfonamide **3** (1.0 equiv), and DIAD (1.1 equiv) according to the general procedure [b](#sec4.2.2){ref-type="other"}, previously reported. The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). The reaction was quenched with slush and extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated under vacuo, and the obtained residue was purified by silica gel column chromatography, eluting with 50% v/v ethyl acetate/*n*-hexane to afford the titled compound **4e** as a white solid.

##### *tert*-Butyl 6-(4-Sulfamoylphenoxy)-hexylcarbamate **4e**: {#sec4.2.3.10.1}

42% yield; silica gel TLC *R*~*f*~ 0.35 (ethyl acetate/*n*-hexane 50% v/v); 101--102 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.41 (17H, m), 1.75 (2H, q, *J* 8.0), 2.94 (2H, q, *J* 8.0), 4.08 (1H, t, *J* 5.2, exchange with D~2~O, O*H*), 6.80 (1H, brt, exchange with D2O, N*H*), 7.11 (2H, d, *J* 8), 7.23 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.77 (2H, d, *J* 8); δ~C~ (100 MHz, DMSO-*d*~6~) 23.6, 24.8, 26.4, 29.2, 30.1, 39.5, 68.3, 78.2, 115.4, 128.7, 136.9, 156.3, 162.1. Elemental analysis: calcd C 54.82, H 7.58, N 7.52, S 8.61; found C 54.66, H 7.58, N 7.36, S 8.56; *m*/*z* (ESI negative) 371.25 \[M -- H\]^−^.

#### Synthesis of 2-(4-Sulfamoylphenoxy)-ethylammonium Trifluoroacetate Salt **5a** {#sec4.2.3.11}

![](jm-2014-01497m_0018){#fx11}

TFA (7.0 equiv) was added to a stirring mixture of *tert*-butyl 2-(4-sulfamoylphenoxy)-ethylcarbamate **4a** (0.5 g, 1.0 equiv) in 10 mL of DCM. The reaction was stirred at r.t. according to the general procedure [c](#sec4.2.3){ref-type="other"}, previously reported until starting material was consumed (TLC monitoring). The solvents were evaporated under vacuo, and the obtained residue was triturated with diethyl ether and dried under vacuo to afford the titled compound **5a** as a white solid.

##### 2-(4-Sulfamoylphenoxy)-ethylammonium Trifluoroacetate Salt **5a**: {#sec4.2.3.11.1}

88% yield, mp 142--143 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 3.30 (2H, t, *J* 5.2), 4.27 (2H, t, *J* 5.2), 7.17 (2H, d, *J*, 8.8), 7.29 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.81 (2H, d, *J* 8.8), 8.02 (3H, brt, exchange with D~2~O, N*H*~3~); δ~C~ (100 MHz, DMSO-*d*~6~) 39.2, 65.7, 115.7, 118.2 (d, *J*^1^~C--F~ 299), 128.7, 137.8, 159.4 (q, *J*^2^~C--F~ 31), 161.2; δ~F~ (376 MHz, DMSO-*d*~6~) −73.5 (3F, s). Elemental analysis: calcd C 36.37, H 3.97, N 8.48, S 9.71; found C 36.76, H 3.72, N 8.08, S 10.02; *m*/*z* (ESI positive) 217.08 \[M -- CF~3~COO^--^\]^+^.

#### Synthesis of 3-(4-Sulfamoylphenoxy)-propylammonium Trifluoroacetate Salt **5b.** {#sec4.2.3.12}

![](jm-2014-01497m_0019){#fx12}

*tert*-Butyl 3-(4-sulfamoylphenoxy)-propylcarbamate **4b** (0.8 g, 1.0 equiv) was dissolved in 1,4-dioxane (10.0 mL), followed by addition of TFA (50.0 equiv). The reaction was treated according to the general procedure [c](#sec4.2.3){ref-type="other"}, previously reported (TLC monitoring). The solvents were evaporated under vacuo, and the obtained residue was triturated with diethyl ether and dried under vacuo to afford the titled compound **5b** as a white solid.

##### 3-(4-Sulfamoylphenoxy)-propylammonium Trifluoroacetate Salt **5b**: {#sec4.2.3.12.1}

91% yield, mp 129--130 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 2.05 (2H, pent, *J* 6.4), 3.00 (2H, m,), 4.17 (2H, t, *J* 6.0), 7.12 (2H, d, *J*, 8.8), 7.26 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.78 (3H, brt, exchange with D~2~O, −N*H*~3~), 7.79 (2H, d, *J* 8.8); δ~C~ (100 MHz, DMSO-*d*~6~) 27.6, 37.1, 66.0, 115.43, 118.2 (d, *J*^1^~C--F~ 297), 128.6, 137.3, 159.4 (q, *J*^2^~C--F~ 31) 161.6; δ~F~ (376 MHz, DMSO-*d*~6~) −73.64 (3F, s), Elemental analysis: calcd C 38.37, H 4.39, N 8.14, S 9.31; found C 38.42, H 4.60, N 7.95, S 9.66; *m*/*z* (ESI positive) 231.30 \[M -- CF~3~COO^--^\]^+^.

#### Synthesis of 4-(4-Sulfamoylphenoxy)-butylammonium Trifluoroacetate Salt **5c** {#sec4.2.3.13}

![](jm-2014-01497m_0020){#fx13}

*tert*-Butyl 4-(4-sulfamoylphenoxy)-butylcarbamate **4c** (0.38 g, 1.0 equiv) was dissolved in DCM (5.0 mL), followed by addition of TFA (12.0 equiv). The reaction was treated according to the general procedure c previously reported (TLC monitoring). The solvents were evaporated under vacuo, and the obtained residue was crystallized from IPA to afford the titled compound **5c** as a white solid.

##### 4-(4-Sulfamoyl-phenoxy)-butylammonium Trifluoroacetate Salt **5c**: {#sec4.2.3.13.1}

50% yield; mp 110--111 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.74 (2H, m), 1.83 (2H, m), 2.90 (2H, t, *J* 7.4), 4.11 (2H, t, *J* 6.0), 7.10 (2H, d, *J* 8.0), 7.25 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.79 (5H, m, Ar--H, N*H*~3~^+^); δ~C~ (100 MHz, DMSO-*d*~6~) 24.8, 26.4, 39.5, 68.3, 115.4, 118.2 (d, *J*^1^~C--F~ 298) 128.6, 137.1, 159.15 (q, *J*^2^~C--F~ 31), 161.8; δ~F~ (376 MHz, DMSO-*d*~6~) −73.4 (3F, s). Elemental analysis: calcd C 40.22, H 4.78, N 7.82, S 8.95; found C 40.30, H 4.63, N 7.72, S 9.56; *m*/*z* (ESI positive) 245.17 \[M -- CF~3~COO^--^\]^+^.

#### Synthesis of 5-(4-Sulfamoylphenoxy)-pentylammonium Trifluoroacetate Salt **5d** {#sec4.2.3.14}

![](jm-2014-01497m_0021){#fx14}

*tert*-Butyl 5-(4-sulfamoylphenoxy)-pentylcarbamate 4d (0.46 g, 1.0 equiv) was dissolved in DCM (5.0 mL), followed by addition of TFA (7.0 equiv). The reaction was treated according to the general procedure [c](#sec4.2.3){ref-type="other"}, previously reported (TLC monitoring). The solvents were evaporated under vacuo, and the obtained residue was triturated from diethyl ether to afford the titled compound **5d** as a white solid.

##### 5-(4-Sulfamoylphenoxy)-pentylammonium Trifluoroacetate Salt **5d**: {#sec4.2.3.14.1}

90% yield; mp 121--122 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.50 (2H, m), 1.63 (2H, m), 1.79 (2H, m), 2.85 (2H, m), 4.09 (2H, t, *J* 6.0), 7.10 (2H, d, *J* 9.0), 7.24 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.71 (3H, brt, exchange with D~2~O, N*H*~3~^+^), 7.77 (2H, d, *J* 9.0); δ~C~ (100 MHz, DMSO-*d*~6~) 23.4, 27.6; 28.9, 39.6, 68.6, 115.3, 118.1 (d, *J*^1^~C--F~ 298), 128.6, 137.0, 159.1 (q, *J*^2^~C--F~ 31), 161.9; δ~F~ (376 MHz, DMSO-*d*~6~) −73.5 (3F, s). Elemental analysis: calcd C 41.93, H 5.14, N 7.52, S 8.61; found C 41.73, H 5.23, N 7.25, S 8.34; *m*/*z* (ESI positive) 259.17 \[M-CF~3~COO^--^\]^+^.

#### Synthesis of 6-(4-Sulfamoylphenoxy)-hexylammonium Trifluoroacetate Salt **5e** {#sec4.2.3.15}

![](jm-2014-01497m_0022){#fx15}

*tert*-Butyl 6-(4-sulfamoylphenoxy)-hexylcarbamate 4e (0.10 g, 1.0 equiv) was dissolved in DCM (1.8 mL), followed by addition of TFA (5.0 equiv). The reaction was treated according to the general procedure [c](#sec4.2.3){ref-type="other"}, previously reported (TLC monitoring). The solvents were evaporated under vacuo, and the obtained residue was crystallized from IPA to afford the titled compound **5e** as a white solid.

##### 6-(4-Sulfamoylphenoxy)-hexylammonium Trifluoroacetate Salt **5e**: {#sec4.2.3.15.1}

30% yield; mp 122--123 °C; δ~H~ (400 MHz, DMSO-*d*~6~) 1.45 (4H, m), 1.59 (2H, pent, *J* 7.5), 1.76 (2H, pent, *J* 7.5), 2.82 (2H, t, *J* 7.5), 4.08 (2H, t, *J* 6.5), 7.11 (2H, d, *J* 9.0), 7.25 (2H, brs, exchange with D~2~O, SO~2~N*H*~2~), 7.63 (3H, brt, exchange with D~2~O, N*H*~3~^+^), 7.77 (2H, d, *J* 9.0); δ~C~ (100 MHz, DMSO-*d*~6~) 25.9, 26.4, 27.9, 30.7, 39.7, 68.7, 115.4, 118.1 (d, *J*^1^~C--F~ 298), 128.6, 137.0, 159.3 (q, *J*^2^~C--F~ 31), 162.0; δ~F~ (376 MHz, DMSO-*d*~6~) −73.5 (1F, s). Elemental analysis: calcd C 43.52, H 5.48, N 7.25, S 8.30; found C 43.19, H 5.24, N 6.95, S 8.16; *m*/*z* (ESI positive) 273.40 \[M -- CF~3~COO^--^\]^+^.

General Procedure for Synthesis of Fluorescent Tagged Sulfonamides **7a**--**c** {#sec4.3}
--------------------------------------------------------------------------------

The *O*-alkylbenzenesulfonamide salt **5** (1.0 equiv) and 2-(6-hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-isothiocyanatobenzoic acid **6** (1.0 equiv) were poured into a two-neck flask, and dry DMA (1.0 mL) was added, followed by addition of TEA (1.5 equiv). The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring). It was then quenched with slush and a 6 M aqueous hydrochloric acid solution and then extracted with ethyl acetate (3 × 15 mL). The combined organic layers were washed with H~2~O (3 × 20 mL), dried over Na~2~SO~4~, filtered, and concentrated in vacuo to afford the titled compound **7** as an orange powder.

### Synthesis of 2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[2-(4-sulfamoylphenoxy)-ethyl\]-thioureido}-benzoic Acid **7a** {#sec4.3.1}
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2-(4-Sulfamoylphenoxy)-ethylammonium trifluoroacetate salt **5a** (50 mg, 1.0 equiv) and 2-(6-hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-isothiocyanatobenzoic acid **6** (1.0 equiv) were treated according to the general [procedure](#sec4.3){ref-type="other"} previously reported afford the titled compound **7a** as an orange powder.

#### 2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[2-(4-sulfamoylphenoxy)-ethyl\]-thioureido}-benzoic Acid **7a** {#sec4.3.1.1}

76% yield; silica gel TLC *R*~*f*~ 0.10 (MeOH/DCM 10% v/v); mp 172--173 °C (dec.); δ~H~ (400 MHz, DMSO-*d*~6~) 3.98 (2H, brt), 4.32 (2H, t, *J* 5.2), 6.61--6.66 (4H, m), 6.71 (2H, d, *J* 2.0), 7.23 (5H, m, 3H Ar--H, 2H exchange with D~2~O, SO~2~N*H*~2~), 7.76 (1H, exchange with D~2~O, N*H*), 7.80 (2H Ar--H, d, *J* 8.8), 8.28 (1H, s), 8.35 (1H, exchange with D~2~O, N*H*), 10.11 (1H, exchange with D~2~O, N*H*), 10.15 (2H, exchange with D~2~O, O*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 44.0, 67.1, 84.1, 103.2, 110.7, 113.6, 115.5, 117.6, 125.1, 127.6, 128.7, 130.0, 130.6, 137.4, 142.1, 148.3, 152.9, 160.5, 161.7, 169.5, 181.8 (*C*=S). Elemental analysis: calcd C 57.51, H 3.83, N 6.94, S 10.59; found C 57.56, H 4.03, N 6.68, S 10.84; *m*/*z* (ESI positive) 606.50 \[M + H\]^+^.

### Synthesis of 2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[3-(4-sulfamoylphenoxy)-propyl\]-thioureido}-benzoic Acid **7b** {#sec4.3.2}
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3-(4-Sulfamoylphenoxy)-propylammonium trifluoroacetate salt **5b** (50 mg, 1.0 equiv) and 2-(6-hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-isothiocyanatobenzoic acid **6** (1.0 equiv) were treated according to the general procedure e, previously reported, to afford the titled compound **7b** as an orange powder.

#### 2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[3-(4-sulfamoylphenoxy)-propyl\]-thioureido}-benzoic Acid **7b** {#sec4.3.2.1}

83% yield; silica gel TLC *R*~*f*~ 0.40 (MeOH/DCM 20% v/v); mp 185--186 °C (dec); δ~H~ (400 MHz, DMSO-*d*~6~) 2.11 (2H, t, *J* 6.4), 3.72 (2H, brt), 4.18 (2H, t; *J* 5.8), 6.62 (4H, m), 6.71 (2H, s), 7.15 (2H, d, *J* 8.8), 7.23 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.79 (2H, d, *J* 8.8), 8.26 (1H, exchange with D~2~O, N*H*), 10.00 (1H, exchange with D~2~O, N*H*), 10.15 (2H, exchange with D~2~O, O*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 29.0, 41.9, 66.9, 85.2, 103.3, 110.8, 113.7, 115.5, 117.7, 125.1, 127.6, 128.7, 130.1, 130.6, 137.2, 142.4, 148.0, 153.0, 160.6, 162.0, 169.5, 181.6 (*C*=S); *m*/*z* (ESI positive) 621.0 \[M + 2H\]^2+^.

### Synthesis of 2-(6-hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[4-(4-sulfamoylphenoxy)-butyl\]-thioureido}-benzoic Acid **7c** {#sec4.3.3}
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4-(4-Sulfamoylphenoxy)-butylammonium trifluoroacetate salt **5c** (50 mg, 1.0 equiv)and 2-(6-hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-isothiocyanatobenzoic acid **6** (1.0 equiv) were treated according to the general procedure e, previously reported, to afford the titled compound **7c** as an orange powder.

#### 2-(6-Hydroxy-3-oxo-3*H*-xanthen-9-yl)-5-{3-\[4-(4-sulfamoylphenoxy)-butyl\]-thioureido}-benzoic Acid **7c** {#sec4.3.3.1}

79% yield; silica gel TLC *R*~*f*~ 0.70 (MeOH/DCM 20% v/v); mp 200--201 °C (dec); δ~H~ (400 MHz, DMSO-*d*~6~) 1.77--1.87 (4H, m), 3.64 (2H, brs), 4.14 (2H, t, *J* 6.1), 6.60--6.66 (4H, m), 6.71 (2H, d, *J* 2.2), 7.13 (2H, d, *J* 8.8), 7.22 (3H, d, *J* 8.3, Ar--H, 2H exchange with D~2~O, SO~2~N*H*~2~), 7.77 (2H, d, *J* 8.8), 8.30 (2H, s, 1H exchange with D~2~O, N*H*), 10.09 (3H, brs, exchange with D~2~O, 2xO*H*, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 26.4, 26.9, 45.4, 68.5, 85.3, 103.2, 110.0, 113.7, 115.4, 117.1, 126.0, 128.1, 128.7, 129.8, 130.0, 137.1, 141.9, 148.9, 153.1, 160.8, 161.9, 168.6, 182.6 (*C*=S); *m*/*z* (ESI positive) 634.5 \[M + H\]^+^.

General Procedure for Synthesis of Florescent Tagged *O*-Alkyl Benzenesulfonamides **9a**,**b** {#sec4.4}
-----------------------------------------------------------------------------------------------

Compound **5** (1.0 equiv) and \[9-(2-carboxy-4-isothiocyanatophenyl)-6-dimethylaminoxanthen-3-ylidene\]dimethylammonium chloride **8** (1.0 equiv) were poured into a two-neck flask, and dry DMA (1.0 mL) was added, followed by addition of TEA (1.5 equiv). The reaction was stirred at r.t. until starting materials were consumed (TLC monitoring), and then it was quenched with slush and a 6 M aqueous hydrochloric acid solution. The precipitate formed was centrifuged, collected, dried under vacuo, washed with diethyl ether (3 × 10 mL), and dried under vacuo to afford the titled compound **9** as a red powder.

### Synthesis of 9-(2-Carboxy-4-{3-\[2-(4-sulfamoylphenoxy)ethyl\]thioureido}phenyl)-6-dimethylaminoxanthen-3-ylidene\]-dimethylammonium Chloride **9a** {#sec4.4.1}
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2-(4-Sulfamoyl-phenoxy)ethylammonium trifluoroacetate salt **5a** (6.9 mg, 1.0 equiv) and \[9-(2-carboxy-4-isothiocyanatophenyl)-6-dimethylaminoxanthen-3-ylidene\]-dimethylammonium chloride **8** (1.0 equiv) were treated according to the previously reported procedure to afford the titled compound **9a** as a red powder.

#### 9-(2-Carboxy-4-{3-\[2-(4-sulfamoylphenoxy)-ethyl\]-thioureido}-phenyl)-6-dimethylaminoxanthen-3-ylidene\]-dimethylammonium Chloride **9a** {#sec4.4.1.1}

70% yield; silica gel TLC *R*~*f*~ 0.40 (MeOH/DCM 20% v/v); mp 177--178 °C (dec); δ~H~ (400 MHz, DMSO-*d*~6~) 3.30 (12H, s), 3.99 (2H, brt), 4.33 (2H, t, *J* 5.4), 7.00 (4H, m), 7.14 (3H, m), 7.21 (2H, d, *J* 8.8), 7.26 (2H, s, exchange with D~2~O, SO~2~N*H*~2~), 7.41 (1H, m), 7.72 (1H, d, *J* 8.8), 7.81 (2H, d, *J* 8.8), 8.46 (2H, brs, 1H, exchange with D~2~O, N*H*), 10.38 (1H, exchange with D~2~O, N*H*); δ~C~ (100 MHz, DMSO-*d*~6~) 35.1, 41.5, 43.9, 67.1, 97.2, 114.1, 115.3, 122.6, 124.5, 125.9, 128.7, 131.7, 137.5, 142.6, 157.6, 160.2, 161.4, 161.6, 166.8, 167.1 (*C*=O), 181.5 (*C*=S); *m*/*z* (ESI positive) 660.50 \[M -- Cl\]^+^.

### Synthesis of 9-(2-Carboxy-4-{3-\[3-(4-sulfamoyl-phenoxy)-propyl\]-thioureido}-phenyl)-6-dimethylaminoxanthen-3-ylidene\]-dimethylammonium Chloride **9b** {#sec4.4.2}
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3-(4-Sulfamoylphenoxy)-propylammonium trifluoroacetate salt **5b** (7.2 mg, 1.0 equiv) and \[9-(2-carboxy-4-isothiocyanatophenyl)-6-dimethylamino-xanthen-3-ylidene\]-dimethylammonium chloride **8** (1.0 equiv) were treated according to the previously reported procedure to afford the titled compound **9b** as a red powder.

#### 9-(2-Carboxy-4-{3-\[3-(4-sulfamoyl-phenoxy)-propyl\]-thioureido}-phenyl)-6-dimethylamino-xanthen-3-ylidene\]-dimethylammonium Chloride **9b** {#sec4.4.2.1}

74% yield; silica gel TLC *R*~*f*~ 0.30 (MeOH/DCM 20% v/v); mp 192--193 °C (dec); δ~H~ (400 MHz, DMSO-*d*~6~) 3.30 (12H, s), 4.13 (2H, t, *J* 6.2), 4.21 (2H, t, *J* 6.2), 6.98 (3H, m), 7.08--7.25 (8H, m), 7.40 (1H, d, *J* 8.8), 7.75 (1H, d, *J* 8.8), 7.79 (2H, d, *J* 8.8), 7.87 (1H, brs), 7.94 (1H, d, *J* 8.8), 8.58 (1H, brt, exchange with D~2~O, N*H*), 10.51 (1H, brs, exchange with D~2~O, N*H*), 10.65 (1H, s); δ~C~ (100 MHz, DMSO-*d*~6~) 28.8, 35.0, 41.4, 41.5, 66.8, 97.2, 114.2, 115.5, 122.6, 124.2, 127.0, 128.6, 131.7, 137.1, 142.6, 157.7, 160.8, 161.9, 161.6, 166.8, 167.1 (*C*=O), 181.5 (*C*=S); *m*/*z* (ESI positive) 674.42 \[M -- Cl\]^+^.

X-ray Crystallography {#sec4.5}
---------------------

### Co-Crystallization {#sec4.5.1}

Two microliters of a 600 mM concentration of **4c** was added to a 500 μL 1.6 M sodium citrate, 50 mM Tris--HCL pH 7.8 reservoir solution. One microliter of this reservoir solution was added to 5 μL of CA II at a final concentration of 10 mg/mL so that the final drug concentration was at 0.24 mM. Hanging drops were set up, and crystals were seen within 5 days. This was repeated for **5c**.

### Diffraction Data and Collection {#sec4.5.2}

Diffraction data for CA II-**4c** and CA II-**5c** complexes were collected on an in-house R-Axis IV^+2^ image plate detector using a RU-H3R rotating Cu anode (*K*α = 1.5418 Å) operating at 50 kV and 22 mA. Images were collected every 1° with an exposure time of 5 min at a detector distance of 100 mm. The crystal data were integrated, merged and scaled using HKL2000.^[@ref33]^

### Structure Determination {#sec4.5.3}

Phasing was carried out in the PHENIX^[@ref34]^ suite of programs using the Auto Molecular Replacement procedure to obtain the initial phases using a previously solved HCA II structure with water molecules removed (PDB code 3KS3).^[@ref35]^ The graphics program Coot^[@ref36]^ was used to view the electron density map, and the structure was adjusted on the basis of the calculated electron density. Topology files of the inhibitors were generated using the PRODRG^[@ref37]^ server, and these files were used to model the drug into the density generated. Refinement was continued using PHENIX.REFINE until the *R*~crys~ and *R*~free~ were minimized. The geometric restraints of the final model were analyzed using PROCHECK.^[@ref38]^ The data diffraction and final model refinement statistics are summarized in Table [2](#tbl2){ref-type="other"}.

### Normotensive Rabbit IOP Lowering Studies {#sec4.5.4}

Male New Zeland albino rabbits weighing 1500--2000 g were used in these studies. Animals were anaesthetized using Zoletil (tiletamine chloride + zolazepam chloride, 3 mg/kg body weight, i.m. injection) and injected with 0.05 mL hypertonic saline solution (5% in distilled water) into the vitreous of both eyes. IOP was measured by using a digital tonometer (Tomo-Pen Avia Tonometer, Reichert Inc. Depew, NY 14043, USA) prior to hypertonic saline injection (basal) at 1, 2, and 4 h after administration of the drug.^[@cit14a]^ Vehicle (phosphate buffer, pH 7.0 plus DMSO 2%) or drugs were instilled immediately after the injection of hypertonic saline into the conjunctive pocket. Eyes were randomly assigned to different groups. Four different animals were used for the tested compounds. Experiments with animals were conducted in agreement with current ethical guidelines and norms approved by the ethical committee of our university.
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CA

:   carbonic anhydrase

CAI

:   CA inhibitor

DCM

:   dichloromethane

DIAD

:   diisopropyl azodicarboxylate

DIPEA

:   diisopropylethylamine

DMA

:   dimethylacetamide

IOP

:   intraocular pressure

IPA

:   propan-2-ol

*K*~I~

:   inhibition constant

SAR

:   structure--activity relationship

TFA

:   trifluoroacetic acid
